Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 1, 2010, Pages 95-106

  Giuliano, Christopher ^a   Haase, Krystal K ^a   Hall, Ronald ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

critically ill; meningitis; MIC; MRSA; obesity; osteomyelitis; pharmacodynamic; pharmacokinetic; pneumonia; vancomycin

Indexed keywords

VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIAL ENDOCARDITIS; BACTERIAL MENINGITIS; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG PENETRATION; DRUG RESPONSE; HUMAN; HYPOTENSION; INFUSION RELATED REACTION; LOADING DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OBESITY; OSTEOMYELITIS; OTOTOXICITY; PATIENT IDENTIFICATION; PATIENT SELECTION; PHARMACODYNAMICS; PNEUMONIA; REVIEW; SOFT TISSUE INFECTION; STAPHYLOCOCCAL PNEUMONIA; STAPHYLOCOCCAL SKIN INFECTION; THROMBOCYTOPENIA; TREATMENT OUTCOME; DRUG EFFECT; ISOLATION AND PURIFICATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 77954498599     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.09.123     Document Type: Review

References (66)

1. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis. 44(9), 1208-1215 (2007). (Pubitemid 46651246)
2. Soriano A, Marco F, Martinez JA et al. Infuence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46(2), 193-200 (2008). (Pubitemid 351269157)
3. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to effcacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42(6), 2398-2402 (2004). (Pubitemid 38747480)
4. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: effcacy and toxicity. Arch. Intern. Med. 166(19), 2138-2144 (2006). (Pubitemid 44631403)
5. Lodise TP, Miller CD, Graves J et al. Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia. J. Antimicrob. Chemother. 62(5), 1138-1141 (2008).
6. Lodise TP, Graves J, Evans A et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52(9), 3315-3320 (2008)
7. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171, 388-416 (2005).
8. Baddour LM, Wilson WR, Bayer AS et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111(23), e394-e434 (2005).
9. Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. 41(10), 1373-1406 (2005). (Pubitemid 41581713)
10. Rybak M, Lomaestro B, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 66(1), 82-98 (2009).
11. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. North Am. 17(3), 479-501 (2003). (Pubitemid 38029149)
12. Knudsen JD, Fuursted K, Raber S, Espersen F, Frimodt-Moller N. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection. Antimicrob. Agents Chemother. 44(5), 1247-1254 (2000). (Pubitemid 30228302)
13. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet. 43(13), 925-942 (2004). (Pubitemid 39447034)
14. Jeffres MN, Isakow W, Doherty JA et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specifc evaluation of vancomycin pharmacokinetic indices. Chest 130(4), 947-955 (2006). (Pubitemid 44583720)
15. Mohr JF, Murray BE. Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 44(5), 1536-1542 (2007). (Pubitemid 46871498)
16. Rose WE, Leonard SN, Rossi KL, Kaatz GW, Rybak MJ. Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 53(2), 805-807 (2009).
17. Sakoulas G, Gold HS, Cohen RA et al. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J. Antimicrob. Chemother. 57(4), 699-704 (2006).
18. Sakoulas G, Eliopoulos GM, Moellering RC Jr et al. Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J. Infect. Dis. 187(6), 929-938 (2003). (Pubitemid 36337905)
19. Tsuji BT, Rybak MJ, Lau KL, Sakoulas G. Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 51(3), 1089-1091 (2007). (Pubitemid 46355301)
20. Healy DP, Sahai JV, Fuller SH, Polk RE. Vancomycin-induced histamine release and 'red man syndrome': comparison of 1-and 2-hour infusions. Antimicrob. Agents Chemother. 34(4), 550-554 (1990). (Pubitemid 20122281)
21. Pai MP, Mercier RC, Koster SA. Epidemiology of vancomycin-induced neutropenia in patients receiving home intravenous infusion therapy. Ann. Pharmacother. 40(2), 224-228 (2006). (Pubitemid 43269851)
22. Von Drygalski A, Curtis BR, Bougie DW et al. Vancomycin-induced immune thrombocytopenia. N. Engl. J. Med. 356(9), 904-910 (2007). (Pubitemid 46339909)
23. Forouzesh A, Moise PA, Sakoulas G. Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob. Agents Chemother. 53(2), 483-486 (2009).
24. Bailie GR, Neal D. Vancomycin ototoxicity and nephrotoxicity. A review. Med. Toxicol. Adverse Drug Exp. 3(5), 376-386 (1988).
25. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profle and nephrotoxicity among hospitalized patients. Clin. Infect. Dis. 49(4), 507-514 (2009).
26. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective ana lysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin. Ther. 29(6), 1107-1115 (2007). (Pubitemid 47208584)
27. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J. Antimicrob. Chemother. 25(4), 679-687 (1990). (Pubitemid 20167292)
28. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob. Agents Chemother. 52(4), 1330-1336 (2008). (Pubitemid 351521995)
29. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Chemother. 60(4), 788-794 (2007). (Pubitemid 47434257)
30. Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: Eighteenth Informational Supplement. Volume 27-28, January (2008).
31. Prakash V, Lewis JS 2nd, Jorgensen JH. Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob. Agents Chemother. 52(12), 4528 (2008).
32. Sader HS, Rhomberg PR, Jones RN. Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53(7), 3162-3165 (2009).
33. Hsu DI, Hidayat LK, Quist R et al. Comparison of method-specifc vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int. J. Antimicrob. Agents 32(5), 378-385 (2008).
34. Cruciani M, Gatti G, Lazzarini L et al. Penetration of vancomycin into human lung tissue. J. Antimicrob. Chemother. 38(5), 865-869 (1996). (Pubitemid 26413723)
35. Georges H, Leroy O, Alfandari S et al. Pulmonary disposition of vancomycin in critically ill patients. Eur. J. Clin. Microbiol. Infect. Dis. 16(5), 385-388 (1997). (Pubitemid 27271829)
36. Lamer C, de Beco V, Soler P et al. Analysis of vancomycin entry into pulmonary lining fuid by bronchoalveolar lavage in critically ill patients. Antimicrob. Agents Chemother. 37(2), 281-286 (1993). (Pubitemid 23046569)
37. Viladrich PF, Gudiol F, Linares J et al. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob. Agents Chemother. 35(12), 2467-2472 (1991).
38. Ricard JD, Wolff M, Lacherade JC et al. Levels of vancomycin in cerebrospinal fuid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study. Clin. Infect. Dis. 44(2), 250-255 (2007). (Pubitemid 46079990)
39. Daschner FD, Frank U, Kummel A et al. Pharmacokinetics of vancomycin in serum and tissue of patients undergoing open-heart surgery. J. Antimicrob. Chemother. 19(3), 359-362 (1987). (Pubitemid 17028005)
40. Graziani AL, Lawson LA, Gibson GA, Steinberg MA, MacGregor RR. Vancomycin concentrations in infected and noninfected human bone. Antimicrob. Agents Chemother. 32(9), 1320-1322 (1988).
41. Skhirtladze K, Hutschala D, Fleck T et al. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob. Agents Chemother. 50(4), 1372-1375 (2006).
42. Rybak MJ, Albrecht LM, Berman JR, Warbasse LH, Svensson CK. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob. Agents Chemother. 34(5), 792-795 (1990). (Pubitemid 20142400)
43. Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO Jr. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob. Agents Chemother. 21(4), 575-580 (1982). (Pubitemid 12070524)
44. Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur. J. Clin. Pharmacol. 54(8), 621-625 (1998). (Pubitemid 28531423)
45. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther. Drug Monit. 16(5), 513-518 (1994). (Pubitemid 24296745)
46. Llopis-Salvia P, Jimenez-Torres N V. Population pharmacokinetic parameters of vancomycin in critically ill patients. J. Clin. Pharm. Ther. 31(5), 447-454 (2006). (Pubitemid 44337293)
47. del Mar Fernandez de Gatta Garcia M, Revilla N, Calvo MV, Dominguez-Gil A, Sanchez Navarro A. Pharmacokinetic/pharmacodynamic ana lysis of vancomycin in ICU patients. Intensive Care Med. 33(2), 279-285 (2007). (Pubitemid 46221233)
48. Dailly E, Le Floch R, Deslandes G, Pannier M, Jolliet P. Infuence of glomerular fltration rate on the clearance of vancomycin administered by continuous infusion in burn patients. Int. J. Antimicrob. Agents 31(6), 537-539 (2008).
49. Scheetz MH, Wunderink RG, Postelnick MJ, Noskin GA. Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy 26(4), 539-550 (2006).
50. Nix DE, Goodwin SD, Peloquin CA, Rotella DL, Schentag JJ. Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning. Antimicrob. Agents Chemother. 35(10), 1947-1952 (1991).
51. Arda B, Yamazhan T, Sipahi OR et al. Meningitis due to methicillin-resistant Staphy loco ccus aureus (MRSA): review of 10 cases. Int. J. Antimicrob. Agents 25(5), 414-418 (2005). (Pubitemid 40558774)
52. Albanese J, Leone M, Bruguerolle B et al. Cerebrospinal fuid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob. Agents Chemother. 44(5), 1356-1358 (2000). (Pubitemid 30228320)
53. Fernandez Guerrero ML, Gonzalez Lopez JJ, Goyenechea A, Fraile J, de Gorgolas M. Endocarditis caused by Staphylococcus aureus: a reappraisal of the epidemiologic, clinical, and pathologic manifestations with ana lysis of factors determining outcome. Medicine (Baltimore) 88(1), 1-22 (2009).
54. Nakayama H, Echizen H, Tanaka M, Sato M, Orii T. Reduced vancomycin clearance despite unchanged creatinine clearance in patients treated with vancomycin for longer than 4 weeks. Ther. Drug Monit. 30(1), 103-107 (2008). (Pubitemid 351161107)
55. Bone and joint infections. In: Pharmacotherapy, A Pathophysiologic Approach (7th Edition). DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (Eds). Appleton & Lange, CT, USA (2008).
56. Vancomycin, package insert. Baxter Healthcare Corporation, IL, USA (2008).
57. Hall RG 2nd, Payne KD, Bain AM et al. Multicenter evaluation of vancomycin dosing: emphasis on obesity. Am. J. Med. 121(6), 515-518 (2008). (Pubitemid 351695516)
58. Vance-Bryan K, Guay DR, Gilliland SS, Rodvold KA, Rotschafer JC. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob. Agents Chemother. 37(3), 436-440 (1993). (Pubitemid 23072585)
59. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular fltration rate from serum creatinine: a new prediction equation. Modifcation of Diet in Renal Disease Study Group. Ann. Intern. Med. 130(24), 461-470 (1999). (Pubitemid 29135798)
60. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 16(1), 31-41 (1976).
61. Matzke GR, Kovarik JM, Rybak MJ, Boike SC. Evaluation of the vancomycin-clearance: creatinine-clearance relationship for predicting vancomycin dosage. Clin. Pharm. 4(3), 311-315 (1985). (Pubitemid 15025314)
62. Murphy JE, Gillespie DE, Bateman CV Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters. Am. J. Health Syst. Pharm. 63(23), 2365-2370 (2006). (Pubitemid 44851779)
63. Wang JT, Fang CT, Chen YC, Chang SC. Necessity of a loading dose when using vancomycin in critically ill patients. J. Antimicrob. Chemother. 47(2), 246 (2001).
64. Klepser ME, Patel KB, Nicolau DP, Quintiliani R, Nightingale CH. Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. Pharmacotherapy 18(5), 1069-1074 (1998). (Pubitemid 28439992)
65. James JK, Palmer SM, Levine DP, Rybak MJ. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented Gram-positive infections. Antimicrob. Agents Chemother. 40(3), 696-700 (1996). (Pubitemid 26071537)
66. Wysocki M, Delatour F, Faurisson F et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob. Agents Chemother. 45(9), 2460-2467 (2001). (Pubitemid 32801896)